DATA: THE ROOT
Of ALL ... GOOD?
nostrapharmus suggests that the drug community will share a single data set
across research, development, marketing, safety and more.
ncreasingly, the ability to store, manipulate, and • Understanding market size
query vast quantities of data is enabling us to • Spotting demographic/health trends
perform key business and medical analysis, without • Recruitment for clinical trials
the need for much of the legwork of old. Not only • Early detection of safety issues
is it easier than ever to structure and query data, • Vastly improved capacity for observational trials
but also the advent of data mining has also opened up new • Linkage of molecular form to clinical function.
opportunities to learn from a wider range of data and from
older, unstructured data. The challenge
The computer age has prepared us well for this new era. Numerous challenges lie ahead, and the competitive threat
Data have been captured in digitized form for a few decades. introduced through the sharing of much of the data will be a
As time has progressed, the data set of every business in major concern for all of the commercial contributors across
the sector has grown. This data, newly generated data, and the pharmaceutical and healthcare sectors. However, in much
everyone else’s data, now present the chance to unearth new the same way as clinical trial data are shared across industry
knowledge, hidden within the depths of the hard drive. systems, patient treatment and outcomes information could
be shared without compromising confidentiality or breaching
The company opportunity data protection laws.
The imperative is already in place, to leverage the data you
have from the development and subsequent commercial use The Way Forward
of your products, to anticipate patient safety issues and to Healthcare and clinical data standards will need to
recognize when patient safety issues are manifesting. This be developed and agreed, data exchange agreements
is clearly good for patients, but it is also unquestionably established and repositories set up. The pharmaceutical
good for business — demonstrating a responsible attitude world is already overloaded with complex safety data
to your ultimate customers, while protecting, and even exchange agreements. These are often out of date compared